Please assess the completion status of the following clinical trial:

Trial Title: A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* LDL-C \> 70 mg/dL and TG \< 400 mg/dL,~* Treated with a stable statin therapy; Atorvastatin 20/40 or Simvastatin 10/20~Exclusion Criteria:~* BMI \> or =35 kg/m2~* Significant cardiovascular disease~* HbA1c \> 10%~* Uncontrolled hypertension~* Active muscle disease~* GFR \< 60 ml/min~* Hepatic dysfunction~* Anemia~* Existing CETP deficiency~* History of Homozygous Familial Hypercholerstrolemia~* History of malignancy~* Alcohol abuse~* Treatment with investigational product~* Treatment with PCSK9~* Clinically significant condition~* Known CETP inhibitor allergy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Once-daily placebo
- 2.5 mg Obicetrapib (Type: EXPERIMENTAL): once-daily Obicetrapib
- 5 mg Obicetrapib (Type: EXPERIMENTAL): once-daily Obicetrapib
- 10 mg Obicetrapib (Type: EXPERIMENTAL): once-daily Obicetrapib

Based on this trial design, predict the completion outcome and termination type (if applicable).